Investors are taking notice as Satellos Bioscience Inc. sees a notable uptick in its stock price.
In the latest trading session, Satellos Bioscience Inc. (MSCL.TO) experienced a solid gain of 2.66%, closing at CA$8.10. This positive movement comes amid ongoing developments in the company's clinical trials and strategic initiatives.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$267.68M
52W high
$18.98
52W low
$6.36
1W change
+10.04%
Beta
1.17
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 39.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+39.0% Upside
Current Price
C$12.71
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
94.6%
Annualized
90-Day Vol
95.9%
Annualized
Trend (90d)
+27.3%
Annualized drift
90d Mean
C$14.01
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$13.13 | C$9.47 โ C$18.20 |
| 60 trading days | C$13.56 | C$8.55 โ C$21.52 |
| 90 trading days | C$14.01 | C$7.96 โ C$24.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The recent rise in Satellos Bioscience's stock reflects growing investor confidence, particularly as the company progresses with its clinical trials and prepares for potential listings on larger exchanges.
Satellos Bioscience Inc. Gains 2.66% in One Day
The stock's rise to CA$8.10 reflects increased investor interest and confidence in the company's future prospects.
Bull case
Investors are feeling optimistic about Satellos's progress in its Phase 2 clinical trials for SAT-3247, which targets Duchenne muscular dystrophy. The company's recent financial results, showing strong equity financing, add to the confidence in its growth potential.
Bear case
Even with the positive movement, investors should stay cautious. Satellos is still a small-cap company that hasnโt turned a profit yet and relies heavily on successful clinical outcomes, which can be unpredictable.
Recent Performance
Satellos Bioscience Inc. closed the last trading session at CA$8.10, marking a 2.66% increase. This uptick is a positive sign for investors, particularly as the company continues to make strides in its clinical programs.
Clinical Advancements
The company's ongoing Phase 2 clinical trials for SAT-3247 are generating excitement among investors. Recent presentations of interim data have shown promising results, which may contribute to the stock's upward momentum.
Future Outlook
Looking ahead, Satellos's plans for a potential Nasdaq listing and its focus on innovative treatments for Duchenne muscular dystrophy could further enhance its market position. Investors should keep an eye on upcoming announcements that may impact stock performance. For more details, check out the latest updates on Satellos Bioscience Inc..
Advertisement
